ClinicalTrials.gg
RecruitingNCT05115214SpherePVIUpdated Sep 15, 2026

Safety and Performance of the Affera SpherePVI™ Multi-Ablation System to Treat Paroxysmal Atrial Fibrillation

An interventional study of SpherePVI™ Catheter in Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions. Recruiting at 2 sites in Czechia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Medtronic Cardiac Ablation Solutions (part of Medtronic) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Atrial Fibrillation by Medtronic — 8 open to participants now, 12 under way, none of them phase 3. Atrial Fibrillation · Medtronic.

Planned enrollment
34th of 66
150 · median 155
Started
2021
with 4 others
No phase
45 of 84
6 open now
Primary completion
2029-09
later than 9 of 11 live
Registered
71st of 84
by date

Among the 84 studies in Atrial Fibrillation by Medtronic, this one is the 34th largest by planned enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2021, is one of 45 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 71st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 84 studies in Atrial Fibrillation by Medtronic are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Atrial Fibrillation by Medtronic, or all of them as a file.
02

Study summary

A prospective, single-arm, multi-center study to evaluate the safety, performance, and effectiveness of the Affera SpherePVI™ Multi-Ablation System for treating paroxysmal atrial fibrillation.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Symptomatic paroxysmal or persistent atrial fibrillation (PAF) documented by:

    • A physician's note indicating recurrent AF
    • At least two electrocardiographically documented AF episodes within 12 months prior to enrollment
  2. Failure or intolerance of at least one Class I-IV anti-arrhythmic drug.
  3. Suitable candidate for catheter ablation.
  4. Age ≥ 18 and \< 75 years.
  5. Able and willing to give .
  6. Able and willing, and has ample means to comply with all pre-procedure, post-procedure and follow-up testing requirements.

Exclusion criteria

Exclusion Criteria:

Subjects will not be eligible for the study if any of the following criteria are met:

  1. Continuous AF lasting more than 12 months (long-standing persistent AF).
  2. AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, or reversible or non-cardiac cause.
  3. Previous left atrial catheter or surgical ablation (including septal closure or left atrial appendage closure).
  4. Valvular cardiac surgical/percutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).
  5. Any carotid stenting or endarterectomy.
  6. Any cardiac procedure (surgical or percutaneous) or percutaneous coronary intervention within 90 days prior to the initial procedure.
  7. Coronary artery bypass graft (CABG) procedure within the 6 months prior to the index ablation procedure.
  8. Awaiting cardiac transplantation or other cardiac surgery within 12 months following the initial ablation procedure.
  9. Presence of any type of implantable cardiac defibrillator (with or without biventricular pacing function).
  10. Documented thromboembolic event (stroke or ) within the past 6 months (180 days).
  11. Documented left atrial thrombus on imaging.
  12. History of blood clotting or bleeding abnormalities.
  13. Any condition contraindicating chronic anticoagulation.
  14. Myocardial infarction (MI) within the 3 months (90 days) prior to the initial procedure.
  15. >40 kg/m2.
  16. Left atrial diameter (anteroposterior) >50 mm for paroxysmal AF and >55mm for persistent AF.
  17. Diagnosed atrial myxoma.
  18. (EF) \< 40%.
  19. Uncontrolled heart failure or Class III or IV heart failure.
  20. Rheumatic heart disease.
  21. Hypertrophic cardiomyopathy.
  22. Unstable angina.
  23. Moderate to severe mitral valve stenosis.
  24. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2).
  25. Primary pulmonary hypertension.
  26. Significant restrictive or obstructive pulmonary disease or chronic respiratory condition.
  27. Renal failure requiring dialysis.
  28. Acute illness, active systemic infection, or sepsis.
  29. Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would impact the scientific soundness of the clinical trial results.
  30. Any woman known to be pregnant or breastfeeding, or any woman of who is not on a reliable form of birth regulation method or abstinence.
  31. Current or anticipated participation in any other clinical trial of a drug, device, or biologic during the duration of the study, unless pre-approved by the Sponsor.
  32. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation.
  33. Known drug or alcohol dependency.
  34. less than 12 months.
  35. Vulnerable subject.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    SpherePVI™ Catheter

    Subjects treated with the SpherePVI™ Catheter

    Device: SpherePVI™ Catheter

Interventions

  • DeviceSpherePVI™ Catheter

    Affera SpherePVI™ Multi-Ablation System

06

What researchers measure

Primary outcomes

  1. Percentage of subjects experiencing a primary safety event

    The primary safety outcome is the incidence of the following serious device-related Primary Adverse Events (AEs) occurring within 7 days of the index ablation procedure: * Death * Myocardial infarction * Persistent phrenic nerve palsy * Transient ischemic attack (TIA) * Stroke/cerebrovascular accident (CVA) * Thromboembolism * Major vascular access complications / bleeding * Heart block * Gastroparesis * Severe pericarditis * Hospitalization (initial and prolonged) due to cardiovascular or pulmonary AE * Cardiac tamponade / perforation (up to 30 days) * Pulmonary vein stenosis (up to 180 days) * Atrio-esophageal fistula (up to 180 days)

    Time frame: 6 months

  2. Percentage of subjects with acute procedure success

    The primary efficacy outcome is acute electrical isolation of all pulmonary veins using the study device. Acute electrical isolation of all pulmonary veins is defined as confirmation of entrance block in all targeted pulmonary veins.

    Time frame: Index ablation procedure

Secondary outcomes

  1. Percentage of subjects experiencing a device- or procedure-related serious adverse event

    The secondary safety outcome is the proportion of subjects experiencing device- or procedure-related serious adverse events (SAEs) as assessed at each follow-up visit

    Time frame: 12 months

  2. Product performance evaluated on a 5-point semi-quantitative scale ("strongly disagree" to "strongly agree")

    Acute product performance will be evaluated during the procedure and includes the following: * SpherePVI™ Catheter handling sufficient to reach reasonable intended targets, as determined by the physician: * catheter delivery to the desired ablation sites * completion of ablation procedure * safe removal of catheter from the subject * Electroanatomical navigation and/or mapping sufficient to aid the procedure (if used) * Generation of acceptable acute ablation lesions * Acute block across linear ablation lines (e.g. CTI flutter line), if performed

    Time frame: Index ablation procedure

  3. Percentage of subjects free from documented recurrence outside of the blanking period

    Chronic efficacy will be evaluated as freedom from documented arrhythmia recurrence outside of a 90-day blanking period. Failure will be reported as both (i) recurrence of AF and (ii) recurrence of any atrial tachyarrhythmia (AF, atrial tachycardia, or atrial flutter).

    Time frame: 12 Months

  4. Percentage of pulmonary veins remaining isolated at remapping

    Chronic efficacy may also be evaluated during an optional remapping procedure and will include the following: * The number of pulmonary veins that remain isolated * The number of patients with all pulmonary veins isolated * The number of previously ablated lines that remain blocked (when applicable)

    Time frame: 75 days

07

Study locations

2 of 2 sites recruiting
  • Homolka Hospital
    Prague, Czechia
    Recruiting
    • Petr Neužil, MD. PhD · Contact
  • Institute Klinicke a Experimentalni Mediciny
    Prague, Czechia
    Recruiting
    • Petr Peichl, MD. PhD. · Contact
08

References and documents

Publications

  • Reddy VY, Peichl P, Kautzner J, Anter E, Metzner A, Koruth J, Jais P, Rackauskas G, Petru J, Funasako M, Marinskis G, Turagam M, Aidietis A, Selma JM, Nejedlo V, Kueffer F, Tarakji KG, Natale A, Neuzil P. One-year outcomes of a conformable single-shot pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation. Heart Rhythm. 2025 Oct;22(10):2551-2561. doi: 10.1016/j.hrthm.2025.04.031. Epub 2025 Apr 26. PubMed 40294729 ↗
  • Reddy VY, Anter E, Peichl P, Rackauskas G, Petru J, Funasako M, Koruth JS, Marinskis G, Turagam M, Aidietis A, Kautzner J, Natale A, Neuzil P. First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation. Europace. 2024 Mar 30;26(4):euae090. doi: 10.1093/europace/euae090. PubMed 38584468 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Sep 2029, 94 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 94 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Nov 10, 2021
StartActual
Oct 19, 2021
Primary completionEst.
Sep 15, 2029
CompletionEst.
Jan 15, 2030
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05115214
Responsible party
Sponsor
First posted
Nov 10, 2021
Start date
Oct 19, 2021
Primary completion
Sep 15, 2029 (estimated)
Completion
Jan 15, 2030 (estimated)
Last update
Sep 15, 2026

Study contacts

Sandra Jacobs
Contact
sandra.jacobs@medtronic.com
x

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion